ECSP21002804A - Apirasas solubilizadas, métodos y usos - Google Patents

Apirasas solubilizadas, métodos y usos

Info

Publication number
ECSP21002804A
ECSP21002804A ECSENADI20212804A ECDI202102804A ECSP21002804A EC SP21002804 A ECSP21002804 A EC SP21002804A EC SENADI20212804 A ECSENADI20212804 A EC SENADI20212804A EC DI202102804 A ECDI202102804 A EC DI202102804A EC SP21002804 A ECSP21002804 A EC SP21002804A
Authority
EC
Ecuador
Prior art keywords
solubilized
methods
apirases
preventing
design
Prior art date
Application number
ECSENADI20212804A
Other languages
English (en)
Inventor
Boerje Haraldsson
Regina Link
Guido Junge
Max Warncke
Agostino Cirillo
Thomas Huber
Chao Zou
Hilmar Ebersbach
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP21002804A publication Critical patent/ECSP21002804A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01005—Apyrase (3.6.1.5), i.e. ATP diphosphohydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)

Abstract

La invención se refiere al diseño y uso terapéutico de polipéptidos de apirasa solubilizados, composiciones farmacéuticas, usos terapéuticos y métodos útiles para prevenir y tratar el daño tisular.
ECSENADI20212804A 2018-07-18 2021-01-14 Apirasas solubilizadas, métodos y usos ECSP21002804A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18184269 2018-07-18

Publications (1)

Publication Number Publication Date
ECSP21002804A true ECSP21002804A (es) 2021-04-29

Family

ID=62985993

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20212804A ECSP21002804A (es) 2018-07-18 2021-01-14 Apirasas solubilizadas, métodos y usos

Country Status (27)

Country Link
US (2) US12325870B2 (es)
EP (1) EP3824079A1 (es)
JP (2) JP7425784B2 (es)
KR (1) KR102919646B1 (es)
CN (6) CN119162148A (es)
AR (1) AR115790A1 (es)
AU (1) AU2019306821B2 (es)
BR (1) BR112021000586A2 (es)
CA (1) CA3103684A1 (es)
CL (1) CL2021000129A1 (es)
CO (1) CO2021000210A2 (es)
CR (1) CR20210021A (es)
CU (1) CU24746B1 (es)
EA (1) EA202190057A1 (es)
EC (1) ECSP21002804A (es)
IL (1) IL280191A (es)
JO (1) JOP20210008A1 (es)
MA (1) MA53177A (es)
MX (1) MX2021000542A (es)
MY (1) MY203583A (es)
PE (1) PE20210185A1 (es)
PH (1) PH12021550122A1 (es)
SG (1) SG11202011776RA (es)
TW (1) TWI857965B (es)
UY (1) UY38299A (es)
WO (1) WO2020016804A1 (es)
ZA (1) ZA202007187B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY38299A (es) * 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos
EP4157131A4 (en) * 2020-05-28 2024-10-02 Charm Sciences, Inc. METHODS AND ASSEMBLIES FOR SAMPLE ANALYSIS
WO2024023745A1 (en) 2022-07-29 2024-02-01 Novartis Ag Treatment for acute organ injury using cd39, recombinant cd39
KR20250044704A (ko) 2022-07-29 2025-04-01 노파르티스 아게 Cd39 변이체의 개선된 생산
WO2025080755A1 (en) * 2023-10-13 2025-04-17 Nutrition & Biosciences USA 4, Inc. Methods and compositions for aging and mitochondrial health

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6447771B1 (en) 1999-03-19 2002-09-10 Hyseq, Inc. Methods and materials relating to novel CD39-like polypeptides
CA2345382A1 (en) * 1998-10-16 2000-04-27 Immunex Corporation Inhibitors of platelet activation and recruitment
US20020002277A1 (en) * 1998-10-16 2002-01-03 Maliszewski Charles Richard Inhibitors of platelet activation and recruitment
US6867177B2 (en) 1999-08-13 2005-03-15 The Trustees Of Columbia University In The City Of New York CD39/ECTO-adpase as a treatment for thrombotic and ischemic disorders
US7247300B1 (en) 2002-11-07 2007-07-24 Apt Therapeutics, Inc. Therapeutic use of soluble CD39L3
EP1861498A4 (en) 2005-03-17 2009-06-24 Ca Nat Research Council EXPRESSION VECTORS FOR TRANSIENT GENETIC EXPRESSION AND MAMMALIAN CELLS EXPRESSING THE SAME
WO2008002157A1 (en) 2006-06-27 2008-01-03 Agresearch Limited Apyrases and uses thereof
CA2787016C (en) * 2010-01-13 2018-01-23 Apt Therapeutics, Inc. Therapeutic apyrase constructs, apyrase agents, and production methods
WO2011088231A1 (en) 2010-01-13 2011-07-21 Apt Therapeutics, Inc. Apyrase therapy for bleeding conditions
JP6708548B2 (ja) 2013-12-20 2020-06-10 ノバルティス アーゲー 新規真核細胞および目的の生成物を組換え発現させるための方法
EP3083677B1 (en) 2013-12-20 2019-08-28 Novartis AG Novel eukaryotic cells and methods for recombinantly expressing a product of interest
UY38299A (es) 2018-07-18 2020-02-28 Novartis Ag Apirasas solubilizadas, métodos y usos

Also Published As

Publication number Publication date
JP7425784B2 (ja) 2024-01-31
CO2021000210A2 (es) 2021-01-18
MX2021000542A (es) 2021-03-29
CN112424346B (zh) 2024-08-06
US12325870B2 (en) 2025-06-10
CN119020321A (zh) 2024-11-26
CN119020320A (zh) 2024-11-26
CN112424346A (zh) 2021-02-26
AR115790A1 (es) 2021-02-24
CN119020318A (zh) 2024-11-26
KR20210035806A (ko) 2021-04-01
CU20210008A7 (es) 2021-08-06
CN119020319A (zh) 2024-11-26
EP3824079A1 (en) 2021-05-26
TWI857965B (zh) 2024-10-11
US20250179447A1 (en) 2025-06-05
US20220356455A1 (en) 2022-11-10
MY203583A (en) 2024-07-05
JP7853263B2 (ja) 2026-04-28
JOP20210008A1 (ar) 2021-01-12
EA202190057A1 (ru) 2021-08-24
SG11202011776RA (en) 2021-02-25
JP2021529550A (ja) 2021-11-04
KR102919646B1 (ko) 2026-01-29
PH12021550122A1 (en) 2021-09-27
PE20210185A1 (es) 2021-02-02
AU2019306821A1 (en) 2020-12-24
CR20210021A (es) 2021-03-23
TW202016299A (zh) 2020-05-01
IL280191A (en) 2021-03-01
BR112021000586A2 (pt) 2021-04-06
CA3103684A1 (en) 2020-01-23
WO2020016804A1 (en) 2020-01-23
UY38299A (es) 2020-02-28
CL2021000129A1 (es) 2021-08-20
AU2019306821B2 (en) 2022-09-29
MA53177A (fr) 2021-05-26
CN119162148A (zh) 2024-12-20
ZA202007187B (en) 2022-06-29
CU24746B1 (es) 2025-04-04
JP2024023297A (ja) 2024-02-21

Similar Documents

Publication Publication Date Title
CL2021000129A1 (es) Apirasas solubilizadas, métodos y usos
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
SV2018005610A (es) Derivados de oxopiridina sustituidos
MX2018005315A (es) Composiciones y metodos para el tratamiento del cancer.
UY37831A (es) Nuevos derivados de quinolina
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
CO2018008421A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2018009563A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
UY37742A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
MX2017007458A (es) Derivados del factor 21 de crecimiento de fibroblastos (fgf21) y sus usos.
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
CL2016002389A1 (es) Compuestos derivados de amidopiridina, agonista inverso del receptor cannabinoide tipo 2 composicion farmaceutica procedimiento de preparación y uso de los compuestos en el tratamiento o profilaxis del dolor neuropatico, asma, osteoporosis, inflamacion, entre otros.
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CL2018001913A1 (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
CR20160529A (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
MX2017014084A (es) Formulaciones de deposito inyectables.
CL2019002480A1 (es) Derivados de pirazol como inhibidores de bromodominio.
UY36732A (es) Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet
MX383386B (es) Nuevos inhibidores de braf y uso de los mismos para el tratamiento de reacciones cutáneas.
MX2021002444A (es) Compuestos y metodos para el tratamiento de infecciones fungicas.
MX2019009909A (es) Composiciones farmaceuticas para terapia de combinacion.
MX384394B (es) Compuesto para uso en la prevención y tratamiento de enfermedades neurodegenerativas.